3-Methyladenine (3-MA)

Catalog No.S2767 Synonyms: NSC 66389

Molecular Weight(MW): 149.15

3-Methyladenine (3-MA) is a selective PI3K inhibitor for Vps34 and PI3Kγ with IC50 of 25 μM and 60 μM in HeLa cells; blocks class I PI3K consistently, whereas suppression of class III PI3K is transient, and also blocks autophagosome formation. Solutions of 3-MA are best fresh-prepared by heating.

Cited by 115 Publications

Toxicol In Vitro, 2020, 62:104715

PubMed: 31698019 ( click the link to review the publication )

Acta Neuropathol, 2019, 138(1):67-84

PubMed: 30937520 ( click the link to review the publication )

Autophagy, 2019, 22:1-17

PubMed: 31500508 ( click the link to review the publication )

Autophagy, 2019, 15(6):960-975

PubMed: 30681394 ( click the link to review the publication )

Cell Rep, 2019, 27(7):2075-2091.e5

PubMed: 31091447 ( click the link to review the publication )

Cell Death Differ, 2019, 26(6):1077-1088

PubMed: 30341420 ( click the link to review the publication )

Mol Cancer, 2019, 18(1):82

PubMed: 30953511 ( click the link to review the publication )

Mol Ther, 2019, 27(5):1039-1050

PubMed: 30852137 ( click the link to review the publication )

Br J Pharmacol, 2019, 176(9):1282-1297

PubMed: 30767208 ( click the link to review the publication )

Cell Prolif, 2019, 52(3):e12576

PubMed: 30719778 ( click the link to review the publication )

Cells, 2019, 8(3)

PubMed: 30875964 ( click the link to review the publication )

Cells, 2019, 8(5)

PubMed: 31130711 ( click the link to review the publication )

J Immunol, 2019, 10.4049/jimmunol.1900169

PubMed: 31235551 ( click the link to review the publication )

J Cell Physiol, 2019, 10.1002/jcp.28432

PubMed: 30847932 ( click the link to review the publication )

J Cell Physiol, 2019, 10.1002/jcp.28382

PubMed: 30793300 ( click the link to review the publication )

J Cell Physiol, 2019, 234(3):2778-2787

PubMed: 30145832 ( click the link to review the publication )

Exp Neurol, 2019, 311:44-56

PubMed: 30219731 ( click the link to review the publication )

Front Oncol, 2019, 9:387

PubMed: 31157167 ( click the link to review the publication )

Front Cell Neurosci, 2019, 10.3389/fncel.2018.00515

PubMed: 30692914 ( click the link to review the publication )

Int J Biol Sci, 2019, 15(4):882-894

PubMed: 30906218 ( click the link to review the publication )

Cancer Cell Int, 2019, 19:175

PubMed: 31320837 ( click the link to review the publication )

Cancer Cell Int, 2019, 19:7

PubMed: 30627053 ( click the link to review the publication )

Mol Carcinog, 2019, 58(11):2149-2160

PubMed: 31448838 ( click the link to review the publication )

Biomed Pharmacother, 2019, 115:108911

PubMed: 31079001 ( click the link to review the publication )
Cancer Manag Res, 2019, 11:5197-5208

PubMed: 31239774 ( click the link to review the publication )

Drug Metab Dispos, 2019, 47(4):425-435

PubMed: 30745309 ( click the link to review the publication )

Phytomedicine, 2019, 58:152769

PubMed: 31005714 ( click the link to review the publication )

Cell Signal, 2019, 53:327-338

PubMed: 30389500 ( click the link to review the publication )

Brain Res Bull, 2019, 150:1-12

PubMed: 31082455 ( click the link to review the publication )

Cell Biosci, 2019, 9:13

PubMed: 30680089 ( click the link to review the publication )

Prostate, 2019, 79(2):206-214

PubMed: 30345525 ( click the link to review the publication )

J Physiol Sci, 2019, 69(2):263-280

PubMed: 30374841 ( click the link to review the publication )

Chem Biol Interact, 2019, 300:18-26

PubMed: 30611790 ( click the link to review the publication )

Am J Transl Res, 2019, 11(3):1327-1342

PubMed: 30972165 ( click the link to review the publication )

Am J Transl Res, 2019, 11(4):2042-2055

PubMed: 31105816 ( click the link to review the publication )

Exp Eye Res, 2019, 184:126-134

PubMed: 31018117 ( click the link to review the publication )

Toxicol In Vitro, 2019, 55:43-50

PubMed: 30496793 ( click the link to review the publication )

Int J Mol Med, 2019, 43(3):1331-1342

PubMed: 30747215 ( click the link to review the publication )

Int J Mol Med, 2019, 44(2):457-468

PubMed: 31173197 ( click the link to review the publication )

Biosci Rep, 2019, 39(6)

PubMed: 31123166 ( click the link to review the publication )

Neurochem Res, 2019, 44(8):2007-2019

PubMed: 31325156 ( click the link to review the publication )

Neurochem Res, 2019, 44(5):1090-1100

PubMed: 30712242 ( click the link to review the publication )

Biochem Biophys Res Commun, 2019, 516(4):1265-1271

PubMed: 31301767 ( click the link to review the publication )

Microb Pathog, 2019, 120-127

PubMed: 30910719 ( click the link to review the publication )

Biochem Biophys Res Commun, 2019, 508(3):682-689

PubMed: 30528392 ( click the link to review the publication )

Clin Respir J, 2019, 10.1111/crj.13091

PubMed: 31562701 ( click the link to review the publication )

Exp Ther Med, 2019, 17(4):2425-2432

PubMed: 30906429 ( click the link to review the publication )

Ecotoxicol Environ Saf, 2019, 184:109617

PubMed: 31476449 ( click the link to review the publication )
Viruses, 2019, 11(6)

PubMed: 31174294 ( click the link to review the publication )

Redox Biol, 2018, 18:138-157

PubMed: 30014903 ( click the link to review the publication )

Cancer Lett, 2018, 416:24-30

PubMed: 29246644 ( click the link to review the publication )

Cardiovasc Res, 2018, 114(7):1016-1028

PubMed: 29529137 ( click the link to review the publication )

J Exp Clin Cancer Res, 2018, 37(1):156

PubMed: 30012194 ( click the link to review the publication )

Cell Death Dis, 2018, 9(11):1063

PubMed: 30337536 ( click the link to review the publication )

FASEB J, 2018, 10.1096/fj.201800463

PubMed: 29912588 ( click the link to review the publication )

Cell Physiol Biochem, 2018, 46(3):975-985

PubMed: 29680838 ( click the link to review the publication )

Cancer Sci, 2018, 109(9):2706-2716

PubMed: 29945297 ( click the link to review the publication )

J Virol, 2018, 92(8)

PubMed: 29386287 ( click the link to review the publication )

Biomed Pharmacother, 2018, 99:271-277

PubMed: 29334671 ( click the link to review the publication )

Int J Oncol, 2018, 53(1):215-224

PubMed: 29693166 ( click the link to review the publication )

J Environ Sci (China), 2018, 66:182-187

PubMed: 29628085 ( click the link to review the publication )

Brain Res Bull, 2018, 139:105-113

PubMed: 29452253 ( click the link to review the publication )

Exp Cell Res, 2018, 363(2):291-298

PubMed: 29355493 ( click the link to review the publication )

Chem Biol Interact, 2018, 281:11-23

PubMed: 29247643 ( click the link to review the publication )

Am J Transl Res, 2018, 10(4):1229-1236

PubMed: 29736216 ( click the link to review the publication )

Exp Gerontol, 2018, 114:57-66

PubMed: 30399406 ( click the link to review the publication )

Toxicol Lett, 2018, 289:28-41

PubMed: 29518472 ( click the link to review the publication )

Int Immunopharmacol, 2018, 64:308-318

PubMed: 30243066 ( click the link to review the publication )

Arch Biochem Biophys, 2018, 657:31-40

PubMed: 30222953 ( click the link to review the publication )

Drug Des Devel Ther, 2018, 12:2971-2980

PubMed: 30254426 ( click the link to review the publication )

Int J Mol Med, 2018, 41(5):3051-3062

PubMed: 29436589 ( click the link to review the publication )

DNA Cell Biol, 2018, 37(1):7-14

PubMed: 29068712 ( click the link to review the publication )
Exp Dermatol, 2018, 27(1):58-63

PubMed: 28767174 ( click the link to review the publication )

Cell Stress Chaperones, 2018, 23(1):1-12

PubMed: 28608264 ( click the link to review the publication )

Mol Med Rep, 2018, 17(3):4307-4316

PubMed: 29363725 ( click the link to review the publication )

Mol Med Rep, 2018, 18(2):1485-1494

PubMed: 29901107 ( click the link to review the publication )

Arch Med Res, 2018, 49(6):381-390

PubMed: 30573200 ( click the link to review the publication )

EBioMedicine, 2017, 17:45-56

PubMed: 28258923 ( click the link to review the publication )

Br J Cancer, 2017, 117(8):1139-1153

PubMed: 29017179 ( click the link to review the publication )

Front Immunol, 2017, 8:1507

PubMed: 29250056 ( click the link to review the publication )

J Cell Mol Med, 2017, 21(12):3420-3434

PubMed: 28643395 ( click the link to review the publication )

Food Chem Toxicol, 2017, 100:183-196

PubMed: 28025121 ( click the link to review the publication )

Cell Mol Neurobiol, 2017, 37(4):717-728

PubMed: 27430567 ( click the link to review the publication )

Biomed Pharmacother, 2017, 89:973-982

PubMed: 28292026 ( click the link to review the publication )

Front Cell Infect Microbiol, 2017, 7:56

PubMed: 28293544 ( click the link to review the publication )

Food Funct, 2017, 8(12):4657-4667

PubMed: 29159335 ( click the link to review the publication )

Int J Biochem Cell Biol, 2017, 87:54-68

PubMed: 28392376 ( click the link to review the publication )

J Cell Biochem, 2017, 119(7):5538-5550

PubMed: 29384220 ( click the link to review the publication )

Drug Des Devel Ther, 2017, 11:431-439

PubMed: 28243065 ( click the link to review the publication )

Biochem Biophys Res Commun, 2017, 493(1):487-493

PubMed: 28870808 ( click the link to review the publication )

Eur Rev Med Pharmacol Sci, 2017, 21(11):2604-2610

PubMed: 28678325 ( click the link to review the publication )

BMC Complement Altern Med, 2017, 17(1):538

PubMed: 29246220 ( click the link to review the publication )

Mol Med Rep, 2017, 16(5):7237-7244

PubMed: 28944847 ( click the link to review the publication )

Oncol Lett, 2017, 14(2):1959-1966

PubMed: 28789429 ( click the link to review the publication )

J BUON, 2017, 22(6):1554-1562

PubMed: 29332352 ( click the link to review the publication )

Oncotarget, 2017, 8(7):11937-11949

PubMed: 28060760 ( click the link to review the publication )
Comp Biochem Physiol C Toxicol Pharmacol, 2017, 195:52-59

PubMed: 28223193 ( click the link to review the publication )

Toxicol Res (Camb), 2017, 6(3):324-332

PubMed: 30090501 ( click the link to review the publication )

Theranostics, 2016, 6(12):2209-2224

PubMed: 27924158 ( click the link to review the publication )

Brain Pathol, 2016, 26(6):713-723

PubMed: 26613556 ( click the link to review the publication )

Free Radic Biol Med, 2016, 90:230-42

PubMed: 26593748 ( click the link to review the publication )

Cell Death Dis, 2016, 7(6):e2247

PubMed: 27253411 ( click the link to review the publication )

Cell Physiol Biochem, 2016, 38(6):2401-13

PubMed: 27299574 ( click the link to review the publication )

Oxid Med Cell Longev, 2016, 2016:9460462

PubMed: 28119765 ( click the link to review the publication )

Int J Oncol, 2016, 48(4):1710-20

PubMed: 26892093 ( click the link to review the publication )

World J Gastroenterol, 2016, 22(18):4501-14

PubMed: 27182160 ( click the link to review the publication )

Am J Transl Res, 2016, 8(8):3593-602

PubMed: 27648150 ( click the link to review the publication )

Oncol Rep, 2016, 36(6):3363-3370

PubMed: 27779694 ( click the link to review the publication )

Int J Mol Med, 2016, 37(3):679-89

PubMed: 26847839 ( click the link to review the publication )

Int J Mol Med, 2016, 38(3):785-93

PubMed: 27431814 ( click the link to review the publication )

J Mol Neurosci, 2016, 58(4):401-10

PubMed: 26635026 ( click the link to review the publication )

J Biochem, 2016, 10.1093/jb/mvw040

PubMed: 27318358 ( click the link to review the publication )

Sci Rep, 2016, 6:33614

PubMed: 27647162 ( click the link to review the publication )

Am J Cancer Res, 2015, 5(1):125-139

PubMed: 25628925 ( click the link to review the publication )

PLoS One, 2014, 9(12):e114000

PubMed: 25486409 ( click the link to review the publication )

Purity & Quality Control

Choose Selective PI3K Inhibitors

Biological Activity

Description

Targets

Vps34 ^[1] (HeLa cells)	PI3Kγ ^[1] (HeLa cells)
25 μM	60 μM

In vitro

The slight preference for Vps34 prevention by 3-Methyladenine probably arises from a hydrophobic ring specific to Vps34, which encircles the 3-methyl group of 3-Methyladenine. ^[1] 3-Methyladenine has been reported to cause cancer cell death under both normal and starvation conditions. 3-Methyladenine could also suppress cell migration and invasion independently of its ability to inhibit autophagy, implying that 3-Methyladenine possesses functions other than autophagy suppression. 3-Methyladenine elicits caspase-dependent cell death that is independent of autophagy inhibition. Treatment with 5 mM 3-Methyladenine reduces the percentage of glucose-starved HeLa cells displaying GFP-LC3 puncta to 23%. The levels of LC3-I are increasing and the levels of LC3-II are decreasing between 12 and 48 hours in cells that are treated with 3-Methyladenine. Conversion of LC3-I to LC3-II is suppressed by 3-Methyladenine. Treatment of HeLa cells with 3-Methyladenine at 2.5 mM or 5 mM for one day does not affect cell viability, whereas treatment with 10 mM 3-Methyladenine for one day causes a 25.0% decrease in cell viability. Treatment of cells with 2.5, 5 or 10 mM 3-Methyladenine for two days causes 11.5%, 38.0% and 79.4% decrease in viability, respectively. 3-Methyladenine decreases cell viability in a time- and dose-dependent manner. 3-Methyladenine significantly shortens the duration of nocodazole-induced-prometaphase arrest. ^[2] Suppression of autophagy by 3-Methyladenine inhibits SU11274-induced cell death. ^[3] Prolonged treatment with 3-Methyladenine (up to 9 hours) induces significant LC3 I to II conversion in wild type MEFs. Prolonged treatment with 3-Methyladenine, but not wortmannin, markedly increases GFP-LC3 punctuation/aggregation. 3-Methyladenine-induced LC3 conversion and free GFP liberation are ATG7-dependent. 3-Methyladenine treatment leads to evident increase of p62 protein level. 3-Methyladenine increases the p62 level even in Atg5−/− MEFs as well as in cells with DOX-mediated deletion of ATG5. 3-Methyladenine inhibits class I and class III PI3K in different temporal patterns. 3-Methyladenine-induced LC3 I to LC3 II conversion is dramatically compromised in Tsc2−/− cells compared with wild type cells.3-Methyladenine disrupts the anti-autophagic function of mTOR complex 1. ^[4]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
95D	MmDQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUmzcW0>	MUiybC=>	MoTNSG1UVw>?	MoH4doVlfWOnczDndo94fGhiaX7obYJqfG:{eTDl[oZm[3Rib3[gRmROSw>?	MmDZNlU4OTZ3NkG=
A549	MmjrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoLPN41O	MnPiNog>	NUDzSnFnTE2VTx?=	NVTINo8yemWmdXPld{Boem:5dHigbY5pcWKrdH;yfUBm\m[nY4Sgc4YhSkSPQx?=	M{nTZVI2PzF4NU[x
95D	M1;kdmFxd3C2b4Ppd{BCe3OjeR?=	MWW1cW0>	M{TXXVJp	MXTEUXNQ	MlXPbY5pcWKrdIOgRmROSy2rbnT1Z4VlKGGyb4D0c5Rq[yClZXzsJIRm[XSq	MknVNlU4OTZ3NkG=
A549	MnvBRZBweHSxc3nzJGF{e2G7	M2XqWFVuVQ>?	MmDSNog>	MXvEUXNQ	MXrpcohq[mm2czDCSG1ENWmwZIXj[YQh[XCxcITveIlkKGOnbHyg[IVifGh?	MYWyOVcyPjV4MR?=
NBL-W-S	M33sfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEXD[5EydU1?	NIXQXJo3cA>?		NUDrU5F1\W6qYX7j[ZMhT0GQVD22NUB1d3irY3n0fS=>	M1LUPVI2OzJ\|MkKy
NBL-W-S	NGTKPI5CeG:ydH;zbZMhSXO\|YYm=	MnfFNY1O	NHnVcGs3cA>?		MW\pcoNz\WG\|ZYOgZ4VtdCCjcH;weI9{cXNiaX7keYNm\CCkeTDHRW5VNTZz	M2LWbVI2OzJ\|MkKy
A2780cp	M2TEbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUGxcW0>	NGX6e3gycA>?		MYXpcoNz\WG\|ZYOgZ4l{eGyjdHnuMYlv\HWlZXSgZ4VtdCCmZXH0bC=>	NVjNbmwzOjV\|MkK2PVQ>
A549	NInBZXJHfW6ldHnvckBCe3OjeR?=	MknlOY1O	NHn5WHgzcA>?		MkPYd5VxeHKnc4Pld{BUWENiaX7keYNm\CCjY3P1cZVt[XSrb36gc4YhVEN\|LVnJ	NHnDVlQzPTJ6NU[yPC=>
H157	NGDJeGVHfW6ldHnvckBCe3OjeR?=	NXv4dFFIPW2P	NV36TGdNOmh?		M33YSpN2eHC{ZYPz[ZMhW1CFIHnu[JVk\WRiYXPjeY12dGG2aX;uJI9nKEyFMz3JTS=>	NVrhT\|dKOjV{OEW2Nlg>
MDR	MWjBdI9xfG:\|aYOgRZN{[Xl?	MYSxNI1O	NGmwUHE3cA>?		Mn3xd5Rz\W6pdHjlcpMhfGinIIDve4VzKG:oIHHueIlk[W6lZYKg[JJ2\3N?	NXO2bod3OjVyMUm3NFE>
HT-29	MVnBdI9xfG:\|aYOgRZN{[Xl?	MVixcW0>	NVfOenpFPDiq	Ml6xSG1UVw>?	NIXQ[\|lmdmijbnPld{Bjd3K2ZYrvcYljNWmwZIXj[YQh[2WubDD2bYFjcWyrdImgcI9{ew>?	MXKyOFg1OjF3OB?=
Microglia	MmLtRZBweHSxc3nzJGF{e2G7	NX;HUlJqPW2P	NXKwVGtTOjSq		NW\RSXNn\GWlcnXhd4V{KGi7cH;4bYEucW6mdXPl[EBk\WyuIHTlZZRp	NHvt[pozPDhzOE[wNS=>
A2780cp	MUDBdI9xfG:\|aYOgRZN{[Xl?	MVqyMlVuVQ>?	M3rve\|Fp	MknD[IRJOk9?	Mm\w[Y5p[W6lZYOgZ4l{eGyjdHnuMYlv\HWlZXSgZ4VtdCCmZXH0bC=>	NEfjXIYzPDhzN{m0Oi=>
HepG2	MnrnSpVv[3Srb36gRZN{[Xl?	MXy1cW0>	MkTKOIg>		NUflVJV4cW6lcnXhd4V{KEiOIILlcIVie2V?	M33XOlI1PzF\|NUi3
A549	MXXBdI9xfG:\|aYOgRZN{[Xl?	NXvoXHNYPW2P	MXe0PIg>		M3\CTYRm[3KnYYPld{B1cGVicHXyZ4VvfGGpZTDv[kBk\WyuIHTlZZRpKGGwZDDlfJBz\XO\|aX;uJIxmfmWuczDv[kBk[XOyYYPlMVMtKEKnY3zpck0yKGGwZDDMR\|MuUUl?	NEnZXZkzPDdyNkOwNy=>
U2OS	NXnJS2FbSXCxcITvd4l{KEG\|c3H5	NVTC[HpDOTCvTR?=	NX3GWIlPOjSq		M{PXOolvfGWwc3nmbYV{KHSqZTDndo94fGhiaX7obYJqfGmxbjDv[kB1cGViVULPV{Bk\WyuczDpcoR2[2WmIHL5JGRwgA>?	M{PsXFI1PjN7MEGz
Saos-2	MoTPRZBweHSxc3nzJGF{e2G7	MUexNI1O	MUiyOIg>		NYfweZVOcW62ZX7zbYZq\XNidHjlJIdzd3e2aDDpcohq[mm2aX;uJI9nKHSqZTDVNm9UKGOnbHzzJIlv\HWlZXSgZpkhTG:6	NFOzT4YzPDZ\|OUCxNy=>
A549	NHW5PXFCeG:ydH;zbZMhSXO\|YYm=	Mle1NVBuVQ>?	MUK0PIg>		MWDhZ4NmdGW{YYTld{B1cGVicnXkeYN1cW:wIH;mJINmdGxidnnhZoltcXS7IHnu[JVk\WRiYomgVHRZ	MkXiNlQ3OjZ5MkK=
HCT116	MUDBdI9xfG:\|aYOgRZN{[Xl?	MlLCOY1O	M{DMWlI1cA>?		NXfBcmNs\W6qYX7j[ZMhfGinIHHwc5B1d3OrczDpcoR2[2WmIHL5JIFxcWenbnnu	MnPINlQ3OjZ3MkK=
HGC-27	M2XoUGZ2dmO2aX;uJGF{e2G7	NX7We5JIOTCvTR?=	NUGxd5JnOWh?		MkLnbY5pcWKrdIOgeIhmKGOnbHygeoli[mmuaYT5JIxwe3NiYomgVmFFODBzIH;yJG1MNTJ{ME[=	M4D0b\|I1PDF4M{S5
U2OS	NWj5d4RSTnWwY4Tpc44hSXO\|YYm=	MV:wMlUwOW2P	M4jRPVQ5cA>?		MVzpcoR2[2W\|IIPhcIlvd227Y3nuMYlv\HWlZXSgZ4VtdCC4aXHibYxqfHlibH;zdy=>	NHv2XWQzPDN3OEO0Ni=>
MG-63	MkjWSpVv[3Srb36gRZN{[Xl?	NHzHVJkxNjVxMX3N	NX\xdGhkPDiq		NEC2R4NqdmS3Y3XzJJNidGmwb335Z4lvNWmwZIXj[YQh[2WubDD2bYFjcWyrdImgcI9{ew>?	NHS0[pEzPDN3OEO0Ni=>
MG-63	M4HlSWFxd3C2b4Ppd{BCe3OjeR?=	M1Xmb\|AvPS9zbV2=	NGf1cnc{Omh?		NITFV2VmdmijbnPld{B{[Wyrbn;tfYNqdi2rbnT1Z4VlKGOnbHygZZBweHSxc3nz	M4LzflI1OzV6M{Sy
MG-63	Ml3YRZBweHSxc3nzJGF{e2G7	MoH5NVBuVQ>?	M2DwRVEzcA>?		NW\aZ4lP\W6qYX7j[ZMhTFBvaX7keYNm\CCjcH;weI9{cXN?	NHXVO\|AzPDN3OEOwNS=>
NTUB1	NUXWS4J[SXCxcITvd4l{KEG\|c3H5	MnK4OY1O	NVTyNW1WOS53aB?=		NG\xdHVxd3SnboTpZZRmeyClZXzlZ495cWJvaX7keYNm\CCjcH;weI9{cXN?	M3TKeFI1OzR7MUe2
T24	M37HZmFxd3C2b4Ppd{BCe3OjeR?=	M3L3cVVuVQ>?	Mm\nNU42cA>?		NIfLbVBxd3SnboTpZZRmeyClZXzlZ495cWJvaX7keYNm\CCjcH;weI9{cXN?	Mo\DNlQ{PDlzN{[=
SGC-7901	NVPtdoNDSXCxcITvd4l{KEG\|c3H5	MoLxNo1O	NVPiU5pmOWh?		NGrFTnFqdmO{ZXHz[ZMhS0FvNDDpcoR2[2WmIHHwc5B1d3Orcx?=	NEf5VFMzPDN{MUO0NC=>
SMMC-7721	M2L5WmFxd3C2b4Ppd{BCe3OjeR?=	MoDkNo1O	NWLVR\|ZtOWh?		NGjkOGRqdmO{ZXHz[ZMhS0FvNDDpcoR2[2WmIHHwc5B1d3Orcx?=	NYTGNnVTOjR\|MkGzOFA>
ECSCs	NVPuc3dNSXCxcITvd4l{KEG\|c3H5	NFzHfHEyOG2P	NULaZZBLPGh?		NVPj[mMx\GWlcnXhd4V{KHKjcHHtfYNqdi22cnXheIVlKGGyb4D0c5Nqew>?	NHz4VHozPDNzOUGwPS=>
MCF-7	MWnGeY5kfGmxbjDBd5NigQ>?	MmDaNVBuVQ>?	NILrNJUzPGh?		M2PGNolvcGmkaYTzJJRp\SCjdYTvdIhi\3liaX7keYNm\CCkeTDjbIVud3SqZYLhdJkh\HK3Z4O=	NULkV\|BDOjR\|MUW1O\|g>
UOK257	NFvsNJlCeG:ydH;zbZMhSXO\|YYm=	MmT2OY1O	M323elNp		M1vRU4VvcGGwY3XzJJBi[2yrdHH4[YwudWWmaXH0[YQh[XCxcITvd4l{yqB?	MlHvNlQ{ODV4MES=
ACHN-5968	NXPmVVlmSXCxcITvd4l{KEG\|c3H5	NInibHU2dU1?	MXWzbC=>		M130fYVvcGGwY3XzJJBi[2yrdHH4[YwudWWmaXH0[YQh[XCxcITvd4l{yqB?	MX:yOFMxPTZyNB?=
Huh7	NUPC[lZVSXCxcITvd4l{KEG\|c3H5	M{H6R\|JuVQ>?	MVSxNog>	NH\sWnNFVVOR	NW[3TpU3cW6qaXLpeJMhSVqGOEC1OU1qdmS3Y3XkJINmdGxiZHXheIg>	MYCyOFI6PzNyMB?=
Hep3B	M1XkfGFxd3C2b4Ppd{BCe3OjeR?=	MXeycW0>	MXqxNog>	M2PZ[mROW09?	Ml\abY5pcWKrdIOgRXpFQDB3NT3pcoR2[2WmIHPlcIwh\GWjdHi=	MXWyOFI6PzNyMB?=
RKO	M1Tl[mZ2dmO2aX;uJGF{e2G7	M3e0UlJuVQ>?	MmL4NYg>	Mo\0SG1UVw>?	NH3hbVlmdmijbnPld{Bk\WyuIHTlZZRpKGK7IHflcIRidmGveXPpci=>	MWWyOFI6OTd5Nx?=
HepG2 E47	MV\GeY5kfGmxbjDBd5NigQ>?	M1vEelIvPW2P	NIjUNWY1QGh?		M4rIcYlv[3KnYYPld{B1cGVidH;4bYNqfHlib3[gRWEtKEKVTzygZY5lKEOFbES=	MonhNlQzPzN5M{i=
LoVo	M1e4NWFxd3C2b4Ppd{BCe3OjeR?=	MUm1cW0>	NIrIdXo1QGh?		M{HUU4VvcGGwY3XzJGRESS2rbnT1Z4VlKGGyb4D0c5Nqey5?	NHzwU3IzPDJyMUixNi=>
WiDr	MV\GeY5kfGmxbjDBd5NigQ>?	M4nabVExdU1?	NFjlcIYycA>?		MUPpcohq[mm2czDQR2JNNWmwZIXj[YQhVEN\|IFnJJIV5eHKnc4Ppc44>	MUWyOFE6ODR6OR?=
H1299	M4nEdmZ2dmO2aX;uJGF{e2G7	NHnqdlAyOG2P	MYi0bC=>		NF\XUVBqdmO{ZXHz[ZMh[2m\|cHzheIlvNWmwZIXj[YQh[2WubDDk[YF1cA>?	NV3qUmdqOjRzN{OyNFg>
H460	NV;CbG01TnWwY4Tpc44hSXO\|YYm=	NHH2cY0yOG2P	M{LzTVRp		MX7pcoNz\WG\|ZYOgZ4l{eGyjdHnuMYlv\HWlZXSgZ4VtdCCmZXH0bC=>	NFq4XZYzPDF5M{KwPC=>
A549	NXjrT4dxTnWwY4Tpc44hSXO\|YYm=	MVuxNI1O	NWe1Z445PGh?		NHTmW45qdmirYnn0d{BifXSxcHjh[5khcW6mdXPl[EBjgSCrcoLh[IlifGmxbh?=	NGrMXmYzPDF2MkezOS=>
Hep3B	MXnBdI9xfG:\|aYOgRZN{[Xl?	MoPtOY1O	MYWyOIg>		Mo\xZZR1\W63YYTld{BVVkZvzsGgdJJwfGWldHnvckBi\2GrboP0JJNmenWvIIP0ZZJ3[XSrb36tcYVlcWG2ZXSgZZBweHSxc3nz	NX;2No5vOjRyNk[2PVM>
SMMC-7721	M2HKV2Fxd3C2b4Ppd{BCe3OjeR?=	NVr3e5ZpPW2P	MX2yOIg>		NULtPW5E[XS2ZX71ZZRmeyCWTl[t{tEheHKxdHXjeIlwdiCjZ3HpcpN1KHOncoXtJJN1[XK4YYTpc44udWWmaXH0[YQh[XCxcITvd4l{	Mm\WNlQxPjZ4OUO=
HO8910	NVq5WmdHSXCxcITvd4l{KEG\|c3H5	M2DzcFExdU1?	NFrGU2syOmh?		NHvReGJmdmijbnPld{BDOTlvaX7keYNm\CCjcH;weI9{cQ>?	MV2yN\|k5OzZzMB?=
MCF7	MljZSpVv[3Srb36gRZN{[Xl?	NGDwelg2dU1?	MUWyOIg>		NHXvfHFqdmO{ZXHz[ZMhS3WRIHnu[JVk\WRiY3XscEBl\WG2aB?=	MorpNlM6PjJ4Mkm=
HONE-1	MmHESpVv[3Srb36gRZN{[Xl?	M3HYO\|VuVQ>?	M{Xqd\|Fp		M1vad5JmeHKnc4Pld{A3ei2vZXTpZZRm\CCUT2OgdJJw\HWldHnvci=>	NXvTZZB2OjN6OUKzOVg>
HeLa	MWnGeY5kfGmxbjDBd5NigQ>?	MlniNVBuVQ>?	M3iyZVJp		M3fMWJN2eHC{ZYPz[ZMhVEN\|IFnJJIV5eHKnc4Ppd49v	Mn\oNlM5PjR5M{i=
HepG2	NYfBe21[TnWwY4Tpc44hSXO\|YYm=	NE\ibJEyOG2P	MmXiNlRp		M{DXV4lvcGmkaYTzJJNqXEmJQWKtJIFv\CCKQmPTMYlv\HWlZXSgZZV1d3CqYXf5	NYLlNItoOjN6MUewOFA>
SH-SY5Y	M4Pu[WZ2dmO2aX;uJGF{e2G7	M3nSZlFuVQ>?	M2DUTFI1cA>?		MnLvbY5pcWKrdIOgeIhmKGG3dH;wbIFogSCrbnT1Z4VlKGK7IGTPR3A>	M4LOSFI{PzR\|MUS4
SH-SY5Y	NX7QcYdwSXCxcITvd4l{KEG\|c3H5	NY\5NHZ{PW2P	NXHYb4NIOWh?		NI\oelZi[m:uaYPo[ZMh[2WuYYP0do9tKG6ndYLvdJJwfGWldHn2[UBm\m[nY4S=	NV\CRXRFOjN4MUmzPVU>
PC12	M4fLeGZ2dmO2aX;uJGF{e2G7	MoO0NVBuVQ>?	MlmwNlRp	NYraZ3NWf2G2ZYK=	NXzvS2ZJyqCrbnjpZol1eyClaIntc5RzgXC\|aX6tcIls\SCycn;0[YF{d22jbDDhZ5Rqfmm2eT6=	NFrkO4czOzZyM{m3PS=>
OV2008	NH\sbmVCeG:ydH;zbZMhSXO\|YYm=	M1j1NlVuVQ>?	NVOxPIpNOjSq		MnrDZ49vfmW{dIOgSnR[PzJyIIfpeIghS0SGUDDpcpRwKGGwIHHk[Il1cX[nIHXm[oVkfCC2b4fhdoR{KGurbHzpcochd3[jcnnhckBk[W6lZYKgZ4VtdHN?	MoDYNlM2QTJ{OEG=
A2780	M3ry[mFxd3C2b4Ppd{BCe3OjeR?=	M2DuclVuVQ>?	MVSyOIg>		M2X1ZYNwdn[ncoTzJGZVYTd{MDD3bZRpKEOGRGCgbY51dyCjbjDh[IRqfGm4ZTDl[oZm[3RidH;3ZZJleyCtaXzsbY5oKG:4YYLpZY4h[2GwY3XyJINmdGy\|	MX2yN\|U6OjJ6MR?=
Saos-2	MlfWRZBweHSxc3nzJGF{e2G7	NF20cWUydU1?	NX;Gfpd6QT[q		M4TiOYlv[3KnYYPld{Bk\WyuIHTlZZRpKGmwZIXj[YQh[nliUFPY	NE\rOIczOzV4M{G3NS=>
1321N1	NUe4TpNXS3m2b4TvfIlkcXS7IFHzd4F6	NGPGUXo2dU1?	NF3Pc5QzPGh?		MYLwdo91\WO2czDj[YxtKGGpYXnud5QhWEOQLXnu[JVk\WRidH;4bYNqfHl?	NFW1b\|gzOzV{NUK2OS=>
SH-SY5Y	NVnPZmFYS3m2b4TvfIlkcXS7IFHzd4F6	M{XCRlVuVQ>?	NEjp[ZAzPGh?		NEDwOm9qdmO{ZXHz[ZMhWEOQIITvfIlkcXS7	NILHWo0zOzV{NUK2OS=>
HT-29	MXPGeY5kfGmxbjDBd5NigQ>?	MUWxcW0>	MlLUOFgwQT[q		NGS0NGhqdmirYnn0d{BCVVCNIHnu[JVk\XNiYYX0c5Bp[WerYzDj[YxtKGSnYYTo	M3;EeVI{PTB6Mkey
OR6	MUTGeY5kfGmxbjDBd5NigQ>?	M17YdlExdU1?	NF7ySpQ4Omh?		NIHYV4R{fXCycnXzd4V{KEiFVjDy[ZBtcWOjdHnvckBidmRiZn;ycYF1cW:wIH;mJIF2fG:yaHHnc5NwdWW\|	Ml3WNlM{QTV6N{W=
Hela	NUjhN4RITnWwY4Tpc44hSXO\|YYm=	M3jtbVVuVQ>?	M2T5OFI1cA>?		MmflbY5pcWKrdIOgd5Rien[jdHnvck1qdmS3Y3XkJIF2fG:yaHHnfS=>	NIS1PFczOzN7NU[3PS=>
MCF-7	M{GxS2Z2dmO2aX;uJGF{e2G7	Mmn1OY1O	NX:3eoRROjSq		MYXpcohq[mm2czDzeIFzfmG2aX;uMYlv\HWlZXSgZZV1d3CqYXf5	NYToT4FVOjN\|OUW2O\|k>
HUVECs	NESySnlHfW6ldHnvckBCe3OjeR?=	NEXM[Zk{dU1?	M1q3OVI1cA>?		MnzLZoxw[2u\|IITo[UBxem:2ZXP0bZZmKGWoZnXjeEBw\iC{ZYP2[ZJifHKxbDDifUBqdmirYnn0bY5oKGG3dH;wbIFogQ>?	NHznRWIzOzN3OEmyPC=>
T24	MUfGeY5kfGmxbjDBd5NigQ>?	NELnfGsyOG2P	NUjwO5ZHOWh?		M13OVpJm\HWlZYOgeIhmKGOuZXH2ZYdmKG:oIFzDN{Bi\nSncjDiZYlk[WyrbjD0doVifG2nboS=	Ml\INlM{PTRyOEC=
U251MG	MXLGeY5kfGmxbjDBd5NigQ>?	M2PhWlNuVQ>?	M3f4XVFp		MVTzeZBxemW\|c3XzJGxEOy2LSTDwdo91\WmwIHX4dJJme3Orb36=	NYrURYVLOjN\|M{i2NVg>
GTL-16	NIftcpRCeG:ydH;zbZMhSXO\|YYm=	NInvTWc2dU1?	MYCyOIg>		NYDFT\|Y5emWmdXPld{Bk\WyuII\pZYJqdGm2eTDhd{Bkd22yYYLl[EB1dyClZXzsd{B1emWjdHXkJJdqfGhiTVXUJIlvcGmkaYTvdpM>	MmnCNlM{OTN2OUC=
T-47D	M3LISWZ2dmO2aX;uJGF{e2G7	NVH2N4VjOTCvTR?=	NYf1U5lFOmh?		Mn;lbY5pcWKrdIOgZZV1d3CqYXf5JJBzd2Onc4OgZY5lKGmwY4LlZZNmeyC{YYDhcZlkcW5iaX7keYNm\CCjcH;weI9{cXN?	M3vNN\|I{OzByMEK2
PaCa44	NViyWnl6SXCxcITvd4l{KEG\|c3H5	NV;wc\|NDOi53bV2=	MWexbC=>		MnjGdoVlfWOnc9Mg[4VvcXCrbj3t[YRq[XSnZDDhdI9xfG:\|aYO=	NGG1dZMzOzF{NEGxNi=>
MDA-MB231	M1rTe2Z2dmO2aX;uJGF{e2G7	M2[1UFVuVQ>?	NXH1d4I{OWh?		MX7pcoNz\WG\|ZYOgdoV{fmW{YYTyc4wudWWmaXH0[YQh[2G\|cHHz[UBi[3SrdnH0bY9vKGGwZDDj[YxtKGSnYYTo	MkTDNlMxQDh6NUC=
HeLa	MnG4RZBweHSxc3nzJGF{e2G7	MYOxNI1O	Moi0Nog>		NIS5c3Nl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgZ48ufHKnYYTt[Y51KHerdHigVGVK	MUGyN\|AxODF\|NR?=
SK-HEP-1	NUPFT5ZGSXCxcITvd4l{KEG\|c3H5	MmrkNVBuVQ>?	NXXqZoEyOWh?		NWK0[4tweHKxdHXjeJMh[WejaX7zeEBifXSxcHjh[5kh[W6mIHnu[JVk\XNiYYDvdJRwe2m\|IHnuJIJ2\mGuaX6teJJm[XSnZDDj[Yxtew>?	NHLmRlUzOjh3OE[0PS=>
HepG2	MVvBdI9xfG:\|aYOgRZN{[Xl?	M1\zSVNuVQ>?	Mo[2OYg>		MWjy[YR2[2W\|IHPlcIwh[XCxcITvd4l{KGmwZIXj[YQh[nliUVTz	MXSyNlg{PjV7NR?=
MCF-7	NELufHRHfW6ldHnvckBCe3OjeR?=	M2jwRlJuVQ>?	MUOyOIg>		MWTpcohq[mm2czDheZRweGijZ4mgbY5lfWOnZDDifUBVVcLi	NVT2VIJGOjR7N{C2O\|Y>
MDA-MB-231	M3i0SWZ2dmO2aX;uJGF{e2G7	MX[ycW0>	MUCyOIg>		NX7qeplRcW6qaXLpeJMh[XW2b4DoZYd6KGmwZIXj[YQh[nliVF5CpC=>	MXuyOFk4ODZ5Nh?=
MCF-7	MYrGeY5kfGmxbjDBd5NigQ>?	MkTNNo1O	NYq0[I5FPDiq		MmDXdJJwdW:2ZYOgWG0ucW6mdXPl[EBk\WyuIHTlZZRp	M{O3OVI1QTdyNke2
MDA-MB-231	NFfPNpNHfW6ldHnvckBCe3OjeR?=	NIP2R3UzdU1?	NXXYSHhoPDiq		MVrwdo9ud3SnczDUUU1qdmS3Y3XkJINmdGxiZHXheIg>	MWWyOFk4ODZ5Nh?=
PANC-1	M2XuWmFxd3C2b4Ppd{BCe3OjeR?=	M2XpWFFuVQ>?	MWW0PIg>	Ml\ZSG1UVw>?	NGT3PWdmdmijbnPld{Bjd3K2ZYrvcYljNWmwZIXj[YQh[2WubDD2bYFjcWyrdImgcI9{ew>?	MoDjNlQ5PDJzNUi=
MDA-MB 231	MXzBdI9xfG:\|aYOgRZN{[Xl?	MWG1cW0>	NWrtdHlXOC53aB?=		NV\JZVNzdW:mdXzheIV{KFSxY3;tbY7DtsLiaX7keYNm\CCjcH;weI9{cXN?	MoLXNlQ5OzB5OEG=
Microglia	MWnBdI9xfG:\|aYOgRZN{[Xl?	NYX4SZpxPW2P	M{HQU\|I1cA>?		MXXk[YNz\WG\|ZYOgbJlxd3irYT3pcoR2[2WmIHPlcIwh\GWjdHi=	NEmycmgzPDhzOE[wNS=>
A2780cp	M2XIWGFxd3C2b4Ppd{BCe3OjeR?=	NWDX[WV3Oi53bV2=	NYnwRoFOOWh?	NWS0cWNU\GSKMl:=	NWr0dZVM\W6qYX7j[ZMh[2m\|cHzheIlvNWmwZIXj[YQh[2WubDDk[YF1cA>?	M1HzXFI1QDF5OUS2
HepG2	MYHGeY5kfGmxbjDBd5NigQ>?	NX\tUJdJPW2P	M3zqZ\|Rp		MUPpcoNz\WG\|ZYOgZ4VtdHWuYYKgcIV3\Wy\|IH;mJGhNyqB?	M4XuWlI1PzF\|NUi3
U2OS	NFi0XopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn;RNVBuVQ>?	NFO5R3QzPGh?		Mmi1bY51\W6\|aX\p[ZMhfGinIHfyc5d1cCCrbnjpZol1cW:wIHnu[JVk\WRiYomgSI95	M4TRZlI1PjN7MEGz
HCT116	M4LicGFxd3C2b4Ppd{BCe3OjeR?=	M1vYRVVuVQ>?	NXvtTmxwOjSq	MonvSG1UVw>?	NGHZbmtmdmijbnPld{BieGmpZX7pck1qdmS3Y3XkJINmdGxiZHXheIg>	NHm4W2EzPDZ{NkWyNi=>
MCF-7	MVzBdI9xfG:\|aYOgRZN{[Xl?	M4TPbFAvOW2P	M{LtXFZp		MYHlcohidmOnczDzbZJ1cW6xbD3pcoR2[2WmIHHwc5B1d3Orcx?=	MmDqNlI4PTF7OEm=
PC-3	Mm\kRZBweHSxc3nzJGF{e2G7	M1S5fFJuVQ>?	NITpN2ozcA>?		M4Xyb4lv[3KnYYPld{BQWklvaX7keYNm\CClZXzsJIRm[XSq	NF63SmgzOjd2NUW4NC=>
U251	MUnBdI9xfG:\|aYOgRZN{[Xl?	NWXCNWNOPW2P	NGDUZlYzPGh?		MkLtbY5kemWjc3XzJHMyNWmwZIXj[YQh[2WubDDk[YF1cA>?	NGnF[XUzOjV5OUe4PC=>
HeLa	NV\m[nFTSXCxcITvd4l{KEG\|c3H5	M2S0OFVuVQ>?	Mn7YNlRp		MWLpcoR2[2W\|IHPhd5Bie2VvZHXw[Y5l\W62IHPlcIwh\GWjdHi=	NH3hU5YzOjV2NUGyPC=>
A549	NH:xdZJHfW6ldHnvckBCe3OjeR?=	NEPUNIUxNjGvTR?=	Mn35NlRp		NEPCU2p{fXCycnXzd4V{KFOXMUGyO\|QucW6mdXPl[EBk\WyuIHTlZZRp	MluwNlI1PjZ7NkC=
pDCs	NH\iN5FHfW6ldHnvckBCe3OjeR?=	M2[5R\|ExdU1?	NGHWPYIxNjWq		NVO0cYY5yqC{ZXT1Z4V{KHSqZTDpcoR2[3Srb36gc4YhUU[QLd8xJIJ6KHO\|Ul7BOFA>	M{TRPFIzOzl4NUm5
BGC-823	NYHtcY1NTnWwY4Tpc44hSXO\|YYm=	NXrLWJRNPW2P	NFzNcJQzcA>?		Mlf3bY5pcWKrdIOgeIhmKHKjdHWgc4Yh[XW2b4DoZYdq[yClZXzsdy=>	M4jZd\|IzOzJ{MUWy
U937	M2HMc2Z2dmO2aX;uJGF{e2G7	NXnPfFZ3Om2P	MoHiNVJp		NYG3VIJK\GWlcnXhd4V{KHSqZTDheZRweGijZ4mgdoF1cW0EoB?=	MXmyNlE2PTF3MB?=
Marc-145	M1rvSmZ2dmO2aX;uJGF{e2G7	MUW1cW0>	MV:xNk8zPC9\|Nni=		M37QXJJm\HWlZYOgeIhmKFCUUmPWJJRqfGW{czDhcoQhfGinIIDyc5RmcW5iZYjwdoV{e2mxbh?=	NULxfI1uOjJzMUm5NFA>
HBx	NXzaUIpOSXCxcITvd4l{KEG\|c3H5	NWXQTY5qOTCvTR?=	NYX3dHZuPDiq	MUjEUXNQ	MoLTbY5kemWjc3XzJINmdGxiZHXheIg>	MmfmNlIxOjByN{i=
MCF-7	MUHGeY5kfGmxbjDBd5NigQ>?	MnrINVBuVQ>?	MWm0PIg>		NHO4bYtjdG:la4OgZZV1d3CqYXf5JIlv\HWlZXSgZpkh[m:{dHX6c41q[g>?	MVKyNVk{OTl\|Nx?=
RMPI8226	NVKwcJBjTnWwY4Tpc44hSXO\|YYm=	Ml7xOY1O	M1rRTlFp		NUDLOI5We3WycILld5NmeyC2aHWgcIV3\Wxib3[gZZV1d3CqYXf5JJVv\GW{IH71eJJq\W62IHTldIxmfGmxbh?=	NELnemMzOTlzNU[yNC=>
PC12/TetOn	M1rIOWZ2dmO2aX;uJGF{e2G7	MnLlNE4yNzGvTR?=	Mof3NVhp		NV[wXIt3dGWjZIOgeI8h\|rFvc4nuLHdVMSCjY3P1cZVt[XSrb36sJJRwgGmlaYT5MEBidmRib3zp[49u\XJiZn;ycYF1cW:wwrC=	MYmyNVkxPjZ3OR?=
HeLa	NIL6NFFEgXSxdH;4bYNqfHliQYPzZZk>	MV:ycW0>	Mn3SNlRp		M2LmU4lvcGmkaYTld{B1cGViY4n0c5RwgGmlaYT5JI9nKHOrbHnibY5qdiC2bzDI[WxiKGOnbHzzMi=>	M2rQN\|IyQDd3M{i1
Jurkat	NXPaSVR1TnWwY4Tpc44hSXO\|YYm=	MV2xNI1O	MVOxbC=>		MX3k[YNz\WG\|ZYOgeIhmKGW6cILld5Nqd25ib3[gUGM{NUmLIHHu[EB1cGViZn;ycYF1cW:wIH;mJIF2fG:yaHHnc5NwdWW\|	MljQNlE5PjRyM{e=
K562	NUnSZW4zTnWwY4Tpc44hSXO\|YYm=	NYC3W\|FqOTCvTR?=	NWftSXRXOWh?		MXXk[YNz\WG\|ZYOgeIhmKGW6cILld5Nqd25ib3[gUGM{NUmLIHHu[EB1cGViZn;ycYF1cW:wIH;mJIF2fG:yaHHnc5NwdWW\|	MnKzNlE5PjRyM{e=
Nara-H	MlWwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3LIOlVuVQ>?	NYTMfFBKPDiq		NV;Rd4JP\W6qYX7j[ZMhfGWvc3nyc4xqdXW\|bXXkbYF1\WRic4XwdJJme3Orb36gc4YhVmG{YT3IJINmdGxicILvcIln\XKjdHnvci=>	MUSyNVgxPTB\|Mx?=
HUVECs	NH;HVJdHfW6ldHnvckBCe3OjeR?=	MXmxNI1O	NGTC[3IxNjWq		NVzaeolS\GWlcnXhd4V{KHSqZTDBS2UuSlODaX7keYNm\CCjdYTvdIhi\3libHX2[S=>	M{DnV\|IyPDZ6NUmy
HepG2	NXGweHFxSXCxcITvd4l{KEG\|c3H5	MYSycW0>	MV2xbC=>		NVjZdpRp\W6qYX7j[ZMhemGmaXH0bY9vNWmwZIXj[YQh[2WubDDk[YF1cA>?	NVzhPHpMOjF2NUO2PVE>

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	α-SMA / TGF-β / LC-3BI / LC-3B II / Beclin-1 / NF-κB p65; PubMed: 29296191 Oncotarget Western blotting analysed expression of α-SMA, TGF-β, LC-3B, Beclin-1, NF-κB and NF-κBp65 in hepatic stellate cells. caspase-3 / caspase-9 / PARP; PubMed: 25891159 Mol Med Rep EC9706 cell lysates were prepared and subjected to immunoblotting with antibodies against caspase-3, caspase-9 and PARP. The expression ratios in each experiment were determined densitometrically. The results are the averages of triplicate samples. Error bars represent the standard error.P<0.05 vs. IR alone. 3-MA, 3-methyladenine; IR, ionizing radiation; PI, propidum iodide; PARP, poly(ADP ribose) polymerase. VEGF; PubMed: 25891159 Mol Med Rep Effects of autophagy inhibition on the protein expression levels of VEGF. Western blot analysis demonstrated that VEGF protein expression levels were decreased when the EC9706 human esophageal squamous cell carcinoma cells were treated with 3-MA. The results are the averages of triplicate samples. Error bars represent the standard error.P<0.05 vs. IR alone. 3-MA, 3-methyladenine; IR, ionizing radiation; VEGF, vascular endothelial growth factor. APP / BACE1 / ADAM17 / Presenilin 1 / Presenilin 2 / Nicastrin / APH-1 / Pen-2 / LC3-1 / LC3-2; PubMed: 26316755 Neuropsychiatr Dis Treat Presenilin 1, Nicastrin, and Pen-2 were increased with the 3-MA treatment (*P<0.001) while the other component of the γ-secretase complex (APH-1 and Presenilin 2) has no difference. 3-MA, 3-methyladenine; Con, control; APP, amyloid protein precursor.	29296191 25891159 26316755
Immunofluorescence	LC3 / Hif-α / COX2; PubMed: 29039446 Int J Mol Med Chemical interventions of autophagy and ischemic-hypoxic injury, assessed using immunochemical double labeling. Compared with the control group, expression levels of HIF-α and COX2 were altered by chemical intervention. (A) Chemical intervention altered the expression of HIF-α and autophagosmes. Following autophagy antagonist (3-MA) intervention, expression of HIF-α was enhanced, compared with that in the OGD group, and was decreased by the autophagy agonist, rapamycin. In the MHY treatment group, expression of HIF-α was similar to that in the 3-MA group. (B) Chemical intervention showed changes in the expression of COX2 and autophagosomes. Changes in the expression of COX2 were similar to changes in HIF-α. Scale bar, 30 µm. OGD, oxygen-glucose deprivation; HIF-α, hypoxia-inducible factor-α; COX2, cyclooxygenase 2; 3-MA, 3-methyladenine; RP, rapamycin; MHY, MHY1485.	29039446
Growth inhibition assay	Cell viability; PubMed: 26934124 Oncotarget KYSE 180 cells were co-treated with EDHB (40 μg/ml) and various concentrations of 3-MA for 24 h (left) or 48 h (right), and cell viability was determined by WST-8 assays.	26934124

In vivo

3-Methyladenine blocks autophagy through its effect on class III phosphatidylinositol 3-kinase (PI3K). 3-Methyladenine treatment does not alter the degree of hemorrhage compared with the subarachnoid hemorrhage (SAH) group. 3-Methyladenine pretreatment significantly aggravates neurological symptoms when compared with the SAH + vehicle group. Autophagy is decreased when 3-Methyladenine treatment is applied. Conversely, cleaved caspase-3 is markedly up-regulated in the SAH + 3-Methyladenine group. In line with the up-regulation of cleaved caspase-3 expression, the number of TUNEL-positive cells in the right cortex is significantly increased in the SAH + 3-Methyladenine group compared with the SAH + vehicle group. ^[5]

Protocol

Kinase Assay:^[4]	- Collapse Protein degradation assay: HeLa cells are radiolabeled for 24 hours with 0.05 mCi/mL l-[U-¹⁴C]valine. At the end of the labeling period, cells are rinsed three times with PBS. Cells are incubated for the designated times in either full medium or EBSS with or without the presence of 10 mM 3-Methyladenine.
Cell Research:^[2]	- Collapse Cell lines: HeLa cell line Concentrations: 1-10 mM Incubation Time: 24, 48 or 72 hours Method: Cell (such as HeLa cell) viability is determined by a trypan blue exclusion assay. Briefly, after treated with 3-Methyladenine, both adherent and floating cells are collected and suspended in phosphate buffered saline (PBS, pH 7.4) at a final density of 1-2 × 10⁶/mL. An equal volume of 0.4% trypan blue solution (w/v, in PBS) is added to the cell suspension and mixed thoroughly. After incubation at room temperature for 3 min, cell counting is performed using a hemacytometer. (Only for Reference)
Animal Research:^[5]	- Collapse Animal Models: Adult male Sprague–Dawley rats weighing 300-350 g Formulation: Saline Dosages: 400 nM Administration: Intracerebral ventricular (Only for Reference)

References

- Collapse

Solubility (25°C)

In vitro	Water	10 mg/mL warmed (67.04 mM)
	Ethanol	4 mg/mL (26.81 mM)
	DMSO	3 mg/mL warmed (20.11 mM)

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download 3-Methyladenine (3-MA) SDF

Molecular Weight	149.15
Formula	C₆H₇N₅
CAS No.	5142-23-4
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	NSC 66389

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
I'm also wondering whether it can be dissolved in water,or maybe something like culture medium,normal saline solution to form 10mM solution
Answer:
As the reference (http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal. pone.0035665), 3-MA, which was found to inhibit autophagy at concentrations ranging from 1 to 10 mM was directly dissolved into the culture medium at the indicated concentrations. And we tested the solubility of S2767, and found the solubility of 3-MA in DMEM is 31 mg/mL at about 40°C.

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

Selective PI3K Inhibitors

CAL-101 (Idelalisib, GS-1101) : p110δ-selective, IC50=2.5 nM.
Selective PI3K Inhibitors

TGX-221 : p110β-specific, IC50=5 nM.
Most Potent PI3K Inhibitor

BEZ235 (NVP-BEZ235, Dactolisib) : p110α/γ/δ/β, IC50=4 nM/5 nM/7 nM/75 nM.
FDA-approved PI3K Inhibitor

CAL-101 (Idelalisib, GS-1101) : Approved by FDA for Relapsed Chronic Lymphocytic Leukemia, Follicular Lymphoma and Small Lymphocytic Lymphoma.
Newest PI3K Inhibitor

VS-5584 (SB2343) ^New : Potent and selective dual PI3K/mTOR inhibitor for mTOR, PI3Kα/β/δ/γ with IC50 of 3.4 nM and 2.6-21 nM, respectively.

Related PI3K Products

Taselisib (GDC 0032) ^New

Taselisib (GDC 0032) is a potent, next-generation β isoform-sparing PI3K inhibitor targeting PI3Kα/δ/γ with K_i of 0.29 nM/0.12 nM/0.97nM, >10 fold selective over PI3Kβ.

Features:A beta isoform-sparing PI3K inhibitor.
Pilaralisib (XL147) ^New

Pilaralisib (XL147) is a selective and reversible class I PI3K inhibitor for PI3Kα/δ/γ with IC50 of 39 nM/36 nM/23 nM in cell-free assays, less potent to PI3Kβ. Phase 1/2.
GNE-317 ^New

GNE-317 is a potent, brain-penetrant PI3K inhibitor.
LY294002

LY294002 is the first synthetic molecule known to inhibit PI3Kα/δ/β with IC50 of 0.5 μM/0.57 μM/0.97 μM, respectively; more stable in solution than Wortmannin, and also blocks autophagosome formation. It not only binds to class I PI3Ks and other PI3K-related kinases, but also to novel targets seemingly unrelated to the PI3K family.
Idelalisib (CAL-101, GS-1101)

Idelalisib (CAL-101, GS-1101) is a selective p110δ inhibitor with IC50 of 2.5 nM in cell-free assays; shown to have 40- to 300-fold greater selectivity for p110δ than p110α/β/γ, and 400- to 4000-fold more selectivity to p110δ than C2β, hVPS34, DNA-PK and mTOR.
Wortmannin

Wortmannin is the first described PI3K inhibitor with IC50 of 3 nM in a cell-free assay, with little selectivity within the PI3K family. Also blocks autophagosome formation and potently inhibits DNA-PK/ATM with IC50 of 16 nM and 150 nM in cell-free assays.
Dactolisib (BEZ235, NVP-BEZ235)

Dactolisib (BEZ235, NVP-BEZ235) is a dual ATP-competitive PI3K and mTOR inhibitor for p110α/γ/δ/β and mTOR(p70S6K) with IC50 of 4 nM /5 nM /7 nM /75 nM /6 nM in cell-free assays, respectively. Inhibits ATR with IC50 of 21 nM in 3T3^TopBP1-ER cell.
Buparlisib (BKM120, NVP-BKM120)

Buparlisib (BKM120, NVP-BKM120) is a selective PI3K inhibitor of p110α/β/δ/γ with IC50 of 52 nM/166 nM/116 nM/262 nM in cell-free assays, respectively. Reduced potency against VPS34, mTOR, DNAPK, with little activity to PI4Kβ. Phase 2.
Pictilisib (GDC-0941)

Pictilisib (GDC-0941) is a potent inhibitor of PI3Kα/δ with IC50 of 3 nM in cell-free assays, with modest selectivity against p110β (11-fold) and p110γ (25-fold). Phase 2.
Alpelisib (BYL719)

Alpelisib (BYL719) is a potent and selective PI3Kα inhibitor with IC50 of 5 nM in a cell-free assay, and minimal effect on PI3Kβ/γ/δ. Phase 2.

Choose Your Country or Region

By Signaling Pathways

By product type

3-Methyladenine (3-MA)

Cited by 115 Publications

Purity & Quality Control

Choose Selective PI3K Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download 3-Methyladenine (3-MA) SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Tech Support

Frequently Asked Questions

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

Related PI3K Products

Choose Your Country or Region

By Signaling Pathways

By product type

3-Methyladenine (3-MA)

Cited by 115 Publications

Purity & Quality Control

Choose Selective PI3K Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download 3-Methyladenine (3-MA) SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Tech Support

Frequently Asked Questions

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

Related PI3K Products

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)